Combination therapeutics for hepatitis delta virus infection: implications of the tobevibart-elebsiran SOLSTICE phase 2 trial
Translational Gastroenterology and Hepatology · 2026-07 · 11 · 75-75
DOI: 10.21037/tgh-2026-0084 ↗Kurz gefasst
Editorial in der Zeitschrift Translational Gastroenterology and Hepatology, 2026-07. Verfasst von Peter D Block und 1 weiteren Autor:innen. Beteiligte Einrichtung: Section of Digestive Diseases and Yale Liver Center, Yale School of Medicine, New Haven, CT, USA. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
plus elebsiran every 4 weeks or tobevibart monotherapy every 2 weeks for 48 weeks in adults with chronic HDV and compensated liver disease. The primary endpoint was achievement of a composite response defined as an HDV RNA level that was either undetectable or ≥ 2 log 10 international units per milliliter (IU/mL) lower from baseline, plus normalization in alanine aminotransferase (ALT) levels. This endpoint aligns with contemporary HDV trials that seek the dual objectives of virological and biochemical control, as this is associated with clinical outcome improvement (6). Key secondary and exploratory endpoints included assessment of the composite response, virologic response, and ALT response at 48 weeks
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Digestive Diseases and Yale Liver Center, Yale School of Medicine, New Haven, CT, USA.
ORCID-Profile: Joseph K Lim
Zitieren
APA
Block, P. D., & Lim, J. K. (2026). Combination therapeutics for hepatitis delta virus infection: implications of the tobevibart-elebsiran SOLSTICE phase 2 trial. Translational Gastroenterology and Hepatology, 11, 75-75. https://doi.org/10.21037/tgh-2026-0084
Vancouver
Block PD, Lim JK. Combination therapeutics for hepatitis delta virus infection: implications of the tobevibart-elebsiran SOLSTICE phase 2 trial. Translational Gastroenterology and Hepatology. 2026;11:75-75. doi:10.21037/tgh-2026-0084
BibTeX
@article{Block2026,
author = {Block, Peter D and Lim, Joseph K},
title = {Combination therapeutics for hepatitis delta virus infection: implications of the tobevibart-elebsiran SOLSTICE phase 2 trial},
journal = {Translational Gastroenterology and Hepatology},
year = {2026},
volume = {11},
pages = {75--75},
doi = {10.21037/tgh-2026-0084}
}
EUVIMED